Navigation Links
May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO
Date:5/14/2009

Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment

BROOMFIELD, Colo., May 14 /PRNewswire/ -- Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on Monday, June 1st at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a 314 patient study indicate that VeriStrat is predictive of survival benefit in patients with squamous cell carcinoma of the head and neck (SCCHN) treated with epidermal growth factor inhibitors (EGFRIs). According to the data, VeriStrat provides information to help oncologists identify patients most likely to benefit from EGFRI therapy.

In the study, VeriStrat was used to classify outcomes in patients with SCCHN who were treated with gefitinib (G), erlotinib and bevacizumab (E/B), cetuximab (C), or palliative chemotherapy (PC). Gefitinib, erlotinib and cetuximab are EGFRIs with activity in SCCHN. Results from the study show that among patients treated with EGFRIs, VeriStrat predicted an overall survival benefit (G: p=0.007, HR 0.41; E/B: p=0.02, HR 0.20; C: p=0.06, HR-0.26). VeriStrat did not classify survival outcomes in patients treated with palliative chemotherapy (PC: p=0.76, HR 0.88).

"At present, there are no validated diagnostic tests to guide therapy selection for patients with SCCHN. Having a blood test that provides results which will help oncologists decide whether or not to treat head and neck cancer patients with anti-EGFR agents would be a major advancement in the treatment of this disease," stated Ezra Cohen, MD, Associate Professor of Medicine at the University of Chicago and a study investigator.

The data support previous study results in which VeriStrat effectively identified patients with NSCLC who were likely to have good or poor outcomes following treatment with EGFRIs (J Natl Cancer Inst. 2007;99(11):838-46). Additional studies are underway to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs.

A study reporting results evaluating the association of VeriStrat status and genetic features with survival after treatment with erlotinib in patients with NSCLC will also be presented on Saturday, May 30th. For more information on the time and locations of these presentations, visit www.asco.org.

"The data to be presented at ASCO validate our molecular profiling approach to identify patient populations who are most likely to benefit from targeted therapies as well as those who are unlikely to receive any benefit," said Heinrich Roder, D.Phil., Chief Technical Officer at Biodesix. "Biodesix is committed to advancing personalized medicine as we continue our research in identifying the relationship between disease, mass spectrometry profiles and therapies. The data from ASCO, coupled with our previous research, show that VeriStrat is effective at predicting outcomes to therapeutics affecting the EGFR pathway, independent of their specific mode of action, and for tumor types where this is a targeted pathway. This brings us one step closer to a healthcare model that is highly personalized."

About VeriStrat: VeriStrat is a pretreatment serum, proteomic test for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with EGFRIs. Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1000 patients. Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix: Biodesix is a fully integrated molecular diagnostic company enabling personalized medicine using mass spectrometry-based molecular profiling. Working with academic and biopharma collaborators, Biodesix uses its proprietary technology, ProTS(R), to discover and validate diagnostic tests that improve patient outcomes. Biodesix' first product, VeriStrat, is commercially available for physicians to help guide their treatment of patients with non-small cell lung cancer. For more information on Biodesix, visit www.Biodesix.com.

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Biodesix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
2. ESA to Launch Corona(R) ultra(TM) at Pittcon 2009: Booth #1080
3. Hospital Build Asia Exhibition and Congress 2009: Regions Most Comprehensive Healthcare Infrastructure Planning and Development Event to Debut in Singapore
4. National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure
5. Lower Your Grocery Bill, Improve Health In 2009: Top Tips From Dr. Praegers Sensible Foods
6. Pharmacy Technician Certification Board (PTCB) Unveils New Testing Features for 2009: PTCB Exam to be Offered Daily; Test Results Given to Candidates Immediately in 2009
7. 2009: The Year of Health Care Reform? Faith-Based Investors See Doubling of Related Shareholder Resolutions, Growing Public Support From Corporate America
8. Nutrition Software nutrinote 2009: Lose Weight With the Help of a Computer
9. NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco
10. OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions
11. SAGE launching new sports medicine journal in 2009: Sports Health: A Multidisciplinary Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Halfway through ... Medicine has provided preventative dental services to more than 15,900 children 5 years old ... 5 LA pledged $38 million over a span of five years to Western University ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Dec. 3, 2016 Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... , , ...
(Date:12/4/2016)... highly innovative, personalized cell-based treatment for a high-risk form of the most ... Children,s Hospital of Philadelphia today reported new results ... The physician-scientists presented findings at the annual meeting of the ... Continue Reading ... ...
(Date:12/2/2016)... -- bioLytical Laboratories, un líder mundial en test rápidos de enfermedades ... Test , a los miembros de la Kenya Pharmaceutical Association. ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton Health ...
Breaking Medicine Technology: